MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy
| author | |
| created | [InstanceEdit:9657389] Rothfels, Karen, 2019-08-08 |
| dbId | 9657388 |
| displayName | MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy |
| journal | Cancer Res. |
| pages | 445-53 |
| pubMedIdentifier | 21118963 |
| schemaClass | LiteratureReference |
| title | MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy |
| url | http://www.ncbi.nlm.nih.gov/pubmed/21118963 |
| volume | 71 |
| year | 2011 |
Referrals
| (literatureReference) | |
| (author) |
© 2026 Reactome
